Stockholm, July 29, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the biotechnology company ExpreS2ion Biotech Holding AB (EXPRS2) commenced trading today on Nasdaq First North in Stockholm. ExpreS2ion Biotech Holding AB operates in the health care sector and is the 52 nd company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.
ExpreS2ion Biotechnologies ApS was founded in 2010 as a spin out of the S2 expression platform from the Danish company Affitech A/S. The founders were scientists who had developed the platform as employees of initially Pharmexa A/S and following Affitech A/S. In 2016, ExpreS2ion Biotech Holding AB was founded.
“We are very pleased to have achieved this milestone in the company’s development and we look forward to be a part of the Nasdaq Stockholm First North family”, said Martin Roland Jensen, Chairman of the Board of ExpreS2ion Biotech Holding AB.
“We welcome ExpreS2ion Biotech Holding AB to Nasdaq First North”, said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “We look forward to supporting ExpreS2ion Biotech Holding on their journey as a publicly traded company”.
ExpreS2ion Biotech Holding AB has appointed Sedermera Fondkommission as the Certified Adviser.
*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.
About Nasdaq First North
Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.
About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com .
Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.
Cautionary Note Regarding Forward-Looking Statements
The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.
| Media Relations Contact: Christina Malmberg Hägerstrand +46 8 405 65 83 christina.hagerstrand@nasdaq.com |
